Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men

Vikrant V. Sahasrabuddhe, Philip E. Castle, Stephen Follansbee, Sylvia Borgonovo, Diane Tokugawa, Lauren M. Schwartz, Thomas S. Lorey, Brandon J. Lamere, Julia C. Gage, Barbara Fetterman, Sean Boyle, Mark Sadorra, Scott Dahai Tang, Teresa M. Darragh, Nicolas Wentzensen

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background. The prevention of human papillomavirus (HPV)-induced anal cancer in high-risk populations such as human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) remains an urgent priority, given rising incidence rates despite widespread antiretroviral therapy use.Methods. HPV genotypes and anal disease prevalence, by cytology and histopathologic findings, were evaluated among 363 HIV-infected MSM. We modeled fractions of high-grade anal intraepithelial neoplasia (HGAIN) attributable to individual carcinogenic HPV genotypes and estimated the range of the proportion of HGAIN cases potentially preventable by prophylactic HPV vaccines.Results. HPV16 was the most common genotype overall (26.4% of cases) and among HGAIN cases (55%). Prevalence of multiple (≥2) carcinogenic HPV genotypes increased from 30.9% in cases of AIN grade <1 to 76.3% in cases of AIN grade 3 (Ptrend <. 001). The fractions of HGAIN cases attributable to carcinogenic HPV16/18 targeted by currently licensed bivalent and quadrivalent HPV vaccines ranged from 12% to 61.5%, and the fractions attributable to carcinogenic HPV16/18/31/33/45/52/58 targeted by an investigational nonavalent HPV vaccine ranged from 39% to 89.4%.Conclusions. Our analytical framework allows estimation of HGAIN cases attributable to individual HPV genotypes in the context of multiple concurrent HPV infections, which are very common among HIV-infected MSM. Our results suggest that licensed and investigational HPV prophylactic vaccines have the potential to prevent a substantial proportion of HGAIN cases in this population.

Original languageEnglish (US)
Pages (from-to)392-401
Number of pages10
JournalJournal of Infectious Diseases
Volume207
Issue number3
DOIs
StatePublished - Feb 1 2013

Fingerprint

Papillomavirus Vaccines
Genotype
HIV
Neoplasms
Anus Neoplasms
Papillomavirus Infections
Population
Cell Biology
Incidence
Therapeutics

Keywords

  • Anal cancer
  • anal intraepithelial neoplasia
  • attribution
  • genotypes
  • human immunodeficiency virus
  • human papillomavirus
  • men who have sex with men

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. / Sahasrabuddhe, Vikrant V.; Castle, Philip E.; Follansbee, Stephen; Borgonovo, Sylvia; Tokugawa, Diane; Schwartz, Lauren M.; Lorey, Thomas S.; Lamere, Brandon J.; Gage, Julia C.; Fetterman, Barbara; Boyle, Sean; Sadorra, Mark; Tang, Scott Dahai; Darragh, Teresa M.; Wentzensen, Nicolas.

In: Journal of Infectious Diseases, Vol. 207, No. 3, 01.02.2013, p. 392-401.

Research output: Contribution to journalArticle

Sahasrabuddhe, VV, Castle, PE, Follansbee, S, Borgonovo, S, Tokugawa, D, Schwartz, LM, Lorey, TS, Lamere, BJ, Gage, JC, Fetterman, B, Boyle, S, Sadorra, M, Tang, SD, Darragh, TM & Wentzensen, N 2013, 'Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men', Journal of Infectious Diseases, vol. 207, no. 3, pp. 392-401. https://doi.org/10.1093/infdis/jis694
Sahasrabuddhe, Vikrant V. ; Castle, Philip E. ; Follansbee, Stephen ; Borgonovo, Sylvia ; Tokugawa, Diane ; Schwartz, Lauren M. ; Lorey, Thomas S. ; Lamere, Brandon J. ; Gage, Julia C. ; Fetterman, Barbara ; Boyle, Sean ; Sadorra, Mark ; Tang, Scott Dahai ; Darragh, Teresa M. ; Wentzensen, Nicolas. / Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. In: Journal of Infectious Diseases. 2013 ; Vol. 207, No. 3. pp. 392-401.
@article{152f9a2e37f2498d8d8520dab1cc3705,
title = "Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men",
abstract = "Background. The prevention of human papillomavirus (HPV)-induced anal cancer in high-risk populations such as human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) remains an urgent priority, given rising incidence rates despite widespread antiretroviral therapy use.Methods. HPV genotypes and anal disease prevalence, by cytology and histopathologic findings, were evaluated among 363 HIV-infected MSM. We modeled fractions of high-grade anal intraepithelial neoplasia (HGAIN) attributable to individual carcinogenic HPV genotypes and estimated the range of the proportion of HGAIN cases potentially preventable by prophylactic HPV vaccines.Results. HPV16 was the most common genotype overall (26.4{\%} of cases) and among HGAIN cases (55{\%}). Prevalence of multiple (≥2) carcinogenic HPV genotypes increased from 30.9{\%} in cases of AIN grade <1 to 76.3{\%} in cases of AIN grade 3 (Ptrend <. 001). The fractions of HGAIN cases attributable to carcinogenic HPV16/18 targeted by currently licensed bivalent and quadrivalent HPV vaccines ranged from 12{\%} to 61.5{\%}, and the fractions attributable to carcinogenic HPV16/18/31/33/45/52/58 targeted by an investigational nonavalent HPV vaccine ranged from 39{\%} to 89.4{\%}.Conclusions. Our analytical framework allows estimation of HGAIN cases attributable to individual HPV genotypes in the context of multiple concurrent HPV infections, which are very common among HIV-infected MSM. Our results suggest that licensed and investigational HPV prophylactic vaccines have the potential to prevent a substantial proportion of HGAIN cases in this population.",
keywords = "Anal cancer, anal intraepithelial neoplasia, attribution, genotypes, human immunodeficiency virus, human papillomavirus, men who have sex with men",
author = "Sahasrabuddhe, {Vikrant V.} and Castle, {Philip E.} and Stephen Follansbee and Sylvia Borgonovo and Diane Tokugawa and Schwartz, {Lauren M.} and Lorey, {Thomas S.} and Lamere, {Brandon J.} and Gage, {Julia C.} and Barbara Fetterman and Sean Boyle and Mark Sadorra and Tang, {Scott Dahai} and Darragh, {Teresa M.} and Nicolas Wentzensen",
year = "2013",
month = "2",
day = "1",
doi = "10.1093/infdis/jis694",
language = "English (US)",
volume = "207",
pages = "392--401",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men

AU - Sahasrabuddhe, Vikrant V.

AU - Castle, Philip E.

AU - Follansbee, Stephen

AU - Borgonovo, Sylvia

AU - Tokugawa, Diane

AU - Schwartz, Lauren M.

AU - Lorey, Thomas S.

AU - Lamere, Brandon J.

AU - Gage, Julia C.

AU - Fetterman, Barbara

AU - Boyle, Sean

AU - Sadorra, Mark

AU - Tang, Scott Dahai

AU - Darragh, Teresa M.

AU - Wentzensen, Nicolas

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Background. The prevention of human papillomavirus (HPV)-induced anal cancer in high-risk populations such as human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) remains an urgent priority, given rising incidence rates despite widespread antiretroviral therapy use.Methods. HPV genotypes and anal disease prevalence, by cytology and histopathologic findings, were evaluated among 363 HIV-infected MSM. We modeled fractions of high-grade anal intraepithelial neoplasia (HGAIN) attributable to individual carcinogenic HPV genotypes and estimated the range of the proportion of HGAIN cases potentially preventable by prophylactic HPV vaccines.Results. HPV16 was the most common genotype overall (26.4% of cases) and among HGAIN cases (55%). Prevalence of multiple (≥2) carcinogenic HPV genotypes increased from 30.9% in cases of AIN grade <1 to 76.3% in cases of AIN grade 3 (Ptrend <. 001). The fractions of HGAIN cases attributable to carcinogenic HPV16/18 targeted by currently licensed bivalent and quadrivalent HPV vaccines ranged from 12% to 61.5%, and the fractions attributable to carcinogenic HPV16/18/31/33/45/52/58 targeted by an investigational nonavalent HPV vaccine ranged from 39% to 89.4%.Conclusions. Our analytical framework allows estimation of HGAIN cases attributable to individual HPV genotypes in the context of multiple concurrent HPV infections, which are very common among HIV-infected MSM. Our results suggest that licensed and investigational HPV prophylactic vaccines have the potential to prevent a substantial proportion of HGAIN cases in this population.

AB - Background. The prevention of human papillomavirus (HPV)-induced anal cancer in high-risk populations such as human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) remains an urgent priority, given rising incidence rates despite widespread antiretroviral therapy use.Methods. HPV genotypes and anal disease prevalence, by cytology and histopathologic findings, were evaluated among 363 HIV-infected MSM. We modeled fractions of high-grade anal intraepithelial neoplasia (HGAIN) attributable to individual carcinogenic HPV genotypes and estimated the range of the proportion of HGAIN cases potentially preventable by prophylactic HPV vaccines.Results. HPV16 was the most common genotype overall (26.4% of cases) and among HGAIN cases (55%). Prevalence of multiple (≥2) carcinogenic HPV genotypes increased from 30.9% in cases of AIN grade <1 to 76.3% in cases of AIN grade 3 (Ptrend <. 001). The fractions of HGAIN cases attributable to carcinogenic HPV16/18 targeted by currently licensed bivalent and quadrivalent HPV vaccines ranged from 12% to 61.5%, and the fractions attributable to carcinogenic HPV16/18/31/33/45/52/58 targeted by an investigational nonavalent HPV vaccine ranged from 39% to 89.4%.Conclusions. Our analytical framework allows estimation of HGAIN cases attributable to individual HPV genotypes in the context of multiple concurrent HPV infections, which are very common among HIV-infected MSM. Our results suggest that licensed and investigational HPV prophylactic vaccines have the potential to prevent a substantial proportion of HGAIN cases in this population.

KW - Anal cancer

KW - anal intraepithelial neoplasia

KW - attribution

KW - genotypes

KW - human immunodeficiency virus

KW - human papillomavirus

KW - men who have sex with men

UR - http://www.scopus.com/inward/record.url?scp=84872042053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872042053&partnerID=8YFLogxK

U2 - 10.1093/infdis/jis694

DO - 10.1093/infdis/jis694

M3 - Article

VL - 207

SP - 392

EP - 401

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -